vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Laird Superfood, Inc. (LSF). Click either name above to swap in a different company.
Laird Superfood, Inc. is the larger business by last-quarter revenue ($13.3M vs $9.2M, roughly 1.4× Foghorn Therapeutics Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -234.3%, a 221.1% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 15.0%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 16.1%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
FHTX vs LSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $13.3M |
| Net Profit | $-21.7M | $-1.8M |
| Gross Margin | — | 34.1% |
| Operating Margin | -258.2% | -13.5% |
| Net Margin | -234.3% | -13.2% |
| Revenue YoY | 223.8% | 15.0% |
| Net Profit YoY | -11.1% | -341.4% |
| EPS (diluted) | $-0.35 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $13.3M | ||
| Q3 25 | $8.2M | $12.9M | ||
| Q2 25 | $7.6M | $12.0M | ||
| Q1 25 | $6.0M | $11.7M | ||
| Q4 24 | $2.9M | $11.6M | ||
| Q3 24 | $7.8M | $11.8M | ||
| Q2 24 | $6.9M | $10.0M | ||
| Q1 24 | $5.0M | $9.9M |
| Q4 25 | $-21.7M | $-1.8M | ||
| Q3 25 | $-15.8M | $-975.1K | ||
| Q2 25 | $-17.9M | $-362.2K | ||
| Q1 25 | $-18.8M | $-156.2K | ||
| Q4 24 | $-19.5M | $-398.4K | ||
| Q3 24 | $-19.1M | $-166.1K | ||
| Q2 24 | $-23.0M | $-239.1K | ||
| Q1 24 | $-25.0M | $-1.0M |
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
| Q4 25 | -258.2% | -13.5% | ||
| Q3 25 | -226.9% | -7.7% | ||
| Q2 25 | -279.2% | -3.3% | ||
| Q1 25 | -385.0% | -1.9% | ||
| Q4 24 | -840.5% | -4.1% | ||
| Q3 24 | -305.5% | -2.3% | ||
| Q2 24 | -386.6% | -3.4% | ||
| Q1 24 | -558.3% | -11.0% |
| Q4 25 | -234.3% | -13.2% | ||
| Q3 25 | -194.4% | -7.6% | ||
| Q2 25 | -237.3% | -3.0% | ||
| Q1 25 | -316.4% | -1.3% | ||
| Q4 24 | -682.9% | -3.4% | ||
| Q3 24 | -244.9% | -1.4% | ||
| Q2 24 | -333.6% | -2.4% | ||
| Q1 24 | -495.4% | -10.3% |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | — | ||
| Q2 25 | $-0.28 | — | ||
| Q1 25 | $-0.30 | — | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.31 | — | ||
| Q2 24 | $-0.45 | — | ||
| Q1 24 | $-0.59 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $11.5M |
| Total Assets | $198.1M | $19.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $5.1M | ||
| Q3 25 | $89.3M | $5.1M | ||
| Q2 25 | $72.6M | $3.9M | ||
| Q1 25 | $61.0M | $7.0M | ||
| Q4 24 | $55.5M | $8.3M | ||
| Q3 24 | $57.7M | $7.9M | ||
| Q2 24 | $138.9M | $7.6M | ||
| Q1 24 | $79.3M | $7.1M |
| Q4 25 | $-108.5M | $11.5M | ||
| Q3 25 | $-89.7M | $12.8M | ||
| Q2 25 | $-76.7M | $13.4M | ||
| Q1 25 | $-61.7M | $13.3M | ||
| Q4 24 | $-45.5M | $13.2M | ||
| Q3 24 | $-28.3M | $13.1M | ||
| Q2 24 | $-14.3M | $12.6M | ||
| Q1 24 | $-97.5M | $12.7M |
| Q4 25 | $198.1M | $19.2M | ||
| Q3 25 | $205.0M | $18.9M | ||
| Q2 25 | $226.2M | $20.4M | ||
| Q1 25 | $258.7M | $21.5M | ||
| Q4 24 | $284.0M | $19.3M | ||
| Q3 24 | $308.4M | $18.8M | ||
| Q2 24 | $328.6M | $18.0M | ||
| Q1 24 | $255.0M | $17.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $68.4K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $68.4K | ||
| Q3 25 | $-18.9M | $1.2M | ||
| Q2 25 | $-21.0M | $-2.8M | ||
| Q1 25 | $-24.0M | $-1.3M | ||
| Q4 24 | $-24.5M | $339.2K | ||
| Q3 24 | $-21.0M | $305.8K | ||
| Q2 24 | $-25.5M | $642.7K | ||
| Q1 24 | $-29.3M | $-422.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-25.6M | — | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | — | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | — | ||
| Q2 24 | -371.0% | — | ||
| Q1 24 | -583.1% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 2.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FHTX
Segment breakdown not available.
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
